Entecavir tablet is an analogue of guanosine nucleoside that is prescribed to treat:
Chronic infection with the Hepatitis B virus (HBV) is defined as sustained increases in serum aminotransferases or signs of histologically active illness in both adult patients and children (at least 2 years of age) with active viral replication.
Entecavir should be ingested orally once daily, consistently at approximately the same time, on an empty stomach—preferably at least 2 hours after a meal and 2 hours before the next one. Swallow Entecavir tablets whole with water; avoid breaking, chewing, or opening them.
The most frequently observed adverse effects include headaches, fatigue, dizziness, and nausea. Less common side effects associated with Entecavir 1mg and Entecavir 0.5 mg tablets encompass diarrhea, indigestion, vomiting, drowsiness, and insomnia.
Serious complications reported among patients taking Entecavir comprise:
Patients should maintain regular contact with a physician while using Entecavir. It’s advisable to promptly discuss any new symptoms or concurrent medications with your physician.
It’s important for patients to understand that Entecavir treatment doesn’t specifically aim to reduce the risk of transmitting Hepatitis B Virus through blood or sexual contact to others.
Before initiating Entecavir 0.5, patients should undergo an HIV test and continue testing if there’s a chance of HIV exposure.
For patients discontinuing anti-hepatitis B therapy, close monitoring of hepatic function through clinical and laboratory assessments for at least several months is recommended.
Extra caution is necessary when prescribing nucleoside analogues to patients with known risk factors for liver disease.
Prior to taking Entecavir, discuss pregnancy or plans for pregnancy with your healthcare provider.
Patients using Entecavir 0.5 mg should have a discussion with their healthcare provider regarding breastfeeding considerations.
Certain laboratory tests may indicate elevated alanine transaminase (ALT), hematuria, glycosuria, and increased lipase levels. Regular monitoring of hepatic function and blood parameters is advised.
What does Entecavir do?
Entecavir is classified as a nucleoside reverse transcriptase inhibitor (NRTI). Its mechanism involves hindering the multiplication of the hepatitis B virus (HBV) by blocking reverse transcriptase.
When was Entecavir approved?
Entecavir obtained medical approval in 2005. Recognized by the World Health Organization (WHO) as an essential medication, it’s listed among the safest and most effective medicines required within healthcare systems.
What type of medication is Entecavir?
Entecavir belongs to the class of guanosine nucleoside analogue drugs, demonstrating selective activity against the hepatitis B virus (HBV).
The Indian Generic Medicines is a Consultancy and Service company providing access to genuine generic medicines to patients all across the world. We also have own pharmacy named as Indian Generic Medicines which work under compliant distribution guidelines.
© 2024 Indian Generic Medicines. All rights reserved.
